查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594695

口服蛋白質和胜肽市場：按藥物類型、應用分類 - 全球預測 2025-2030

Oral Proteins & Peptides Market by Drug Type (Calcitonin, Insulin, Linaclotide), Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年口服蛋白和胜肽市值為14億美元，預計2024年將達到15.9億美元，複合年成長率為13.37%，預計2030年將達到33.8億美元。

口服蛋白質和胜肽市場包括透過口服途徑提供的基於蛋白質和勝胜肽的療法的開發和商業化。這個市場是由解決糖尿病、癌症和骨質疏鬆症等慢性疾病的需求所驅動的，口服給藥可以顯著提高患者的依從性和治療效果。應用範圍包括藥物治療，透過藥物傳輸技術的進步，傳統上透過注射給藥的勝胜肽已被修改為口服攝取。最終使用目標主要是製藥公司、生物技術公司、研究機構和受託研究機構，旨在擴大對口服生技藥品的需求。

主要市場統計
基準年[2023] 14億美元
預測年份 [2024] 15.9億美元
預測年份 [2030] 33.8億美元
複合年成長率（%） 13.37%

該市場的關鍵成長要素包括奈米技術和口服藥物傳輸系統的進步，這可以生物有效性蛋白質和胜肽的生物利用度和穩定性。需要長期治療方法的慢性病的盛行率日益增加，這是市場擴張的重大機會。此外，值得注意的是，大型製藥企業擴大投資於研發（R&D），以將新的口服生技藥品推向市場。為了充分利用這些機會，公司應該投資於聯合研發夥伴關係和合作。

然而，市場成長受到限制，例如由於胃腸道分解和吸收率變化而導致實現高生物有效性的固有挑戰。此外，與生物治療藥物核准相關的監管複雜性也可能阻礙進展。為了克服這些障礙，該產業可以專注於創新領域，例如設計更穩定的蛋白質結構、利用蛋白酶抑制劑以及開發新型賦形劑和配方技術。

該市場表現出進步的性質，具有顛覆性創新的巨大潛力，可以增強以患者為中心的解決方案。我們的結果表明，對個人化醫療日益成長的興趣正在推動研究和開發，以創造更有針對性和更有效的口服勝胜肽療法。企業應專注於最佳化口服給藥流程，開拓開拓的市場，以建立競爭優勢並有效發展業務。

市場動態：揭示快速發展的口服蛋白質和勝胜肽市場的關鍵市場洞察

供需的動態交互作用正在改變口服蛋白質和勝胜肽市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病增加
    • 增加患者對口服藥物的偏好
    • 口服蛋白質和胜肽所需的材料充足
  • 市場限制因素
    • 口服勝胜肽生產成本高
  • 市場機會
    • 用於口服遞送的奈米粒子的出現
    • 製藥公司加強研發力度
  • 市場挑戰
    • 對不必要的酵素分解和固有結構複雜性的擔憂

波特的五力：駕馭口服蛋白質和胜肽市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解口服蛋白質和胜肽市場的外部影響

外部宏觀環境因素在塑造口服蛋白質和胜肽市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解口服蛋白質和胜肽市場的競爭格局

口服蛋白質和胜肽市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位基質口服蛋白勝胜肽市場供應商績效評估

FPNV定位矩陣是評估口服蛋白和胜肽市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，規劃口服蛋白質和胜肽市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，口服蛋白質和胜肽市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病盛行率增加
      • 更多患者喜歡口服藥物
      • 適合口服蛋白質和胜肽的材料充足
    • 抑制因素
      • 口服勝胜肽生產成本高
    • 機會
      • 口服奈米顆粒的出現
      • 製藥公司加強研發力度
    • 任務
      • 對不必要的酵素分解和固有結構複雜性的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 口服蛋白/勝胜肽市場藥物（依類型）

  • 抑鈣素
  • 胰島素
  • Linaclotide
  • Octreotide
  • Plecanatide

第7章口服蛋白/勝胜肽市場：依應用分類

  • 骨病
  • 糖尿病
  • 胃和消化系統疾病
  • 荷爾蒙失調

第8章美洲口服蛋白和勝胜肽市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太口服蛋白勝胜肽市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲口服蛋白勝胜肽市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Almac Group
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Catalent, Inc.
  • Chiasma, Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Proxima Concepts Limited
  • Sanofi SA
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.59 billion in 2024, and is projected to grow at a CAGR of 13.37%, to USD 3.38 billion by 2030.

The oral proteins and peptides market encompasses the development and commercialization of protein and peptide-based therapeutics delivered via the oral route. This market is driven by the necessity to address chronic diseases such as diabetes, cancer, and osteoporosis, where oral delivery can significantly enhance patient compliance and therapeutic effectiveness. The application scope includes pharmacological treatments where peptides, traditionally administered through injections, are reformulated for oral ingestion thanks to advancements in drug delivery technologies. The end-use spectrum predominantly targets pharmaceutical and biotechnology companies, research institutes, and contract research organizations, aiming to tap into the growing demand for orally administered biologics.

KEY MARKET STATISTICS
Base Year [2023] USD 1.40 billion
Estimated Year [2024] USD 1.59 billion
Forecast Year [2030] USD 3.38 billion
CAGR (%) 13.37%

Critical growth factors in this market include advancements in nanotechnology and oral drug delivery systems, enabling better bioavailability and stability of proteins and peptides. The increasing prevalence of chronic diseases requiring long-term treatment regimens presents substantial opportunities for market expansion. Additionally, increasing investments in research and development (R&D) by major pharmaceutical companies to bring novel oral biologics to market are noteworthy. Companies should invest in partnerships and collaborations for co-research and development to maximize these opportunities.

However, market growth is restricted by limitations such as the inherent challenges in achieving high oral bioavailability due to degradation in the gastrointestinal tract and variable absorption. Furthermore, regulatory complexities associated with the approval of biotherapeutics may also impede progress. To overcome these hurdles, the industry can focus on innovative areas such as designing more stable protein structures, utilizing protease inhibitors, and developing novel excipients and formulation technologies.

The market exhibits a progressive nature, with significant potential for disruptive innovations that enhance patient-centric solutions. Insights suggest a growing interest in personalized medicine, which is driving R&D towards creating more targeted and effective oral peptide therapies. Businesses should focus on optimizing the oral delivery process and exploring untapped markets to establish a competitive edge and foster business growth effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Proteins & Peptides Market

The Oral Proteins & Peptides Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in prevalence of chronic diseases
    • Rise in patient preference for oral drugs
    • Adequate availability of materials for oral delivery of proteins and peptides
  • Market Restraints
    • High manufacturing costs of oral peptides
  • Market Opportunities
    • Emergence of nanoparticles for oral delivery
    • Increase in R&D by pharmaceutical companies
  • Market Challenges
    • Concerns related to unwanted enzymatic degradation and inherent structural complexities

Porter's Five Forces: A Strategic Tool for Navigating the Oral Proteins & Peptides Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Proteins & Peptides Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Proteins & Peptides Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Proteins & Peptides Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Proteins & Peptides Market

A detailed market share analysis in the Oral Proteins & Peptides Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Proteins & Peptides Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Proteins & Peptides Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Proteins & Peptides Market

A strategic analysis of the Oral Proteins & Peptides Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Almac Group, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Catalent, Inc., Chiasma, Inc., Eli Lilly and Company, Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer, Inc., Proxima Concepts Limited, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Oral Proteins & Peptides Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Calcitonin, Insulin, Linaclotide, Octreotide, and Plecanatide.
  • Based on Application, market is studied across Bone Diseases, Diabetes, Gastric & Digestive Disorders, and Hormonal Disorders.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of chronic diseases
      • 5.1.1.2. Rise in patient preference for oral drugs
      • 5.1.1.3. Adequate availability of materials for oral delivery of proteins and peptides
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing costs of oral peptides
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of nanoparticles for oral delivery
      • 5.1.3.2. Increase in R&D by pharmaceutical companies
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to unwanted enzymatic degradation and inherent structural complexities
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Proteins & Peptides Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Calcitonin
  • 6.3. Insulin
  • 6.4. Linaclotide
  • 6.5. Octreotide
  • 6.6. Plecanatide

7. Oral Proteins & Peptides Market, by Application

  • 7.1. Introduction
  • 7.2. Bone Diseases
  • 7.3. Diabetes
  • 7.4. Gastric & Digestive Disorders
  • 7.5. Hormonal Disorders

8. Americas Oral Proteins & Peptides Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Oral Proteins & Peptides Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Oral Proteins & Peptides Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Almac Group
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Biocon Limited
  • 6. Catalent, Inc.
  • 7. Chiasma, Inc.
  • 8. Eli Lilly and Company
  • 9. Merck KGaA
  • 10. Novartis AG
  • 11. Novo Nordisk A/S
  • 12. Oramed Pharmaceuticals Inc.
  • 13. Pfizer, Inc.
  • 14. Proxima Concepts Limited
  • 15. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LINACLOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PLECANATIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY BONE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GASTRIC & DIGESTIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023